Literature DB >> 17549589

Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone.

G Silvestrini1, P Ballanti, M Leopizzi, M Sebastiani, S Berni, M Di Vito, E Bonucci.   

Abstract

Sclerostin, the secreted protein product of the SOST gene, which is mainly expressed by osteocytes, has recently been proposed as a negative regulator of bone osteoblastogenesis. Chronic elevation of PTH reduces SOST expression by osteocytes, while controversial results have been obtained by intermittent PTH administration. We have investigated the effects of intermittently administered PTH on SOST expression and sclerostin localization, comparing them with those of controls, as they appeared in three different bone segments of rat tibia: secondary trabecular metaphyseal and epiphyseal bone, and cortical diaphyseal bone. The histomorphometric results demonstrate that PTH enhances bone turnover through anabolic effects, as shown by the association of increased bone resorption variables with a significant rise in BV/TV, Tb.Th and Tb.N and a fall in Tb.Sp. PTH induces a SOST mRNA and protein fall in secondary metaphyseal trabeculae, diaphyseal bone and in epiphyseal trabeculae. Numbers of sclerostin immunopositive osteocytes/mm(2) show no change, compared with controls; there are fewer sclerostin-positive osteocytes in secondary metaphyseal trabeculae than in the other two bone areas, both in the control and PTH groups. The low numbers of sclerostin-positive osteocytes in the metaphyseal trabecular bone seem to be directly related to the fact that this area displays a high remodeling rate. The anabolic effects of PTH are in line with the fall of SOST mRNA and protein in all the three bone segments examined; the rise of bone turnover supports a negative role of SOST in bone formation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549589     DOI: 10.1007/s10735-007-9096-3

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  27 in total

1.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Authors:  David G Winkler; May Kung Sutherland; James C Geoghegan; Changpu Yu; Trenton Hayes; John E Skonier; Diana Shpektor; Mechtild Jonas; Brian R Kovacevich; Karen Staehling-Hampton; Mark Appleby; Mary E Brunkow; John A Latham
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

2.  Wnt/beta-catenin--a canonical tale of cell-fate choice in the vertebrate skeleton.

Authors:  Elona Kolpakova; Bjorn R Olsen
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

Review 3.  The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Authors:  L C Hofbauer; S Khosla; C R Dunstan; D L Lacey; W J Boyle; B L Riggs
Journal:  J Bone Miner Res       Date:  2000-01       Impact factor: 6.741

4.  Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.

Authors:  T Bellido; A A Ali; I Gubrij; L I Plotkin; Q Fu; C A O'Brien; S C Manolagas; R L Jilka
Journal:  Endocrinology       Date:  2005-08-04       Impact factor: 4.736

5.  Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.

Authors:  Xiaofeng Li; Yazhou Zhang; Heeseog Kang; Wenzhong Liu; Peng Liu; Jianghong Zhang; Stephen E Harris; Dianqing Wu
Journal:  J Biol Chem       Date:  2005-03-18       Impact factor: 5.157

6.  Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells.

Authors:  Takako Tobimatsu; Hiroshi Kaji; Hideaki Sowa; Junko Naito; Lucie Canaff; Geoffrey N Hendy; Toshitsugu Sugimoto; Kazuo Chihara
Journal:  Endocrinology       Date:  2006-02-16       Impact factor: 4.736

7.  Methacarn fixation for genomic DNA analysis in microdissected, paraffin-embedded tissue specimens.

Authors:  Chikako Uneyama; Makoto Shibutani; Naoya Masutomi; Hironori Takagi; Masao Hirose
Journal:  J Histochem Cytochem       Date:  2002-09       Impact factor: 2.479

8.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

9.  Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor.

Authors:  Masaki Kato; Millan S Patel; Regis Levasseur; Ivan Lobov; Benny H-J Chang; Donald A Glass; Christine Hartmann; Lan Li; Tae-Ho Hwang; Cory F Brayton; Richard A Lang; Gerard Karsenty; Lawrence Chan
Journal:  J Cell Biol       Date:  2002-04-15       Impact factor: 10.539

10.  Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.

Authors:  Rutger L van Bezooijen; Bernard A J Roelen; Annemieke Visser; Lianne van der Wee-Pals; Edwin de Wilt; Marcel Karperien; Herman Hamersma; Socrates E Papapoulos; Peter ten Dijke; Clemens W G M Löwik
Journal:  J Exp Med       Date:  2004-03-15       Impact factor: 14.307

View more
  43 in total

1.  Circulating sclerostin in disorders of parathyroid gland function.

Authors:  Aline G Costa; Serge Cremers; Mishaela R Rubin; Donald J McMahon; James Sliney; Marise Lazaretti-Castro; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2011-09-21       Impact factor: 5.958

2.  Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts.

Authors:  Damian C Genetos; Chrisoula A Toupadakis; Leah F Raheja; Alice Wong; Savvas E Papanicolaou; David P Fyhrie; Gabriela G Loots; Clare E Yellowley
Journal:  J Cell Biochem       Date:  2010-05-15       Impact factor: 4.429

Review 3.  Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis.

Authors:  T J Martin; N A Sims; K W Ng
Journal:  Osteoporos Int       Date:  2008-03-13       Impact factor: 4.507

4.  Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.

Authors:  Gerald J Atkins; Peter S Rowe; Hui P Lim; Katie J Welldon; Renee Ormsby; Asiri R Wijenayaka; Lesya Zelenchuk; Andreas Evdokiou; David M Findlay
Journal:  J Bone Miner Res       Date:  2011-07       Impact factor: 6.741

Review 5.  Osteocyte: the unrecognized side of bone tissue.

Authors:  G Y Rochefort; S Pallu; C L Benhamou
Journal:  Osteoporos Int       Date:  2010-03-04       Impact factor: 4.507

6.  Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.

Authors:  Changjun Li; Weishan Wang; Liang Xie; Xianghang Luo; Xu Cao; Mei Wan
Journal:  Ann N Y Acad Sci       Date:  2015-04-02       Impact factor: 5.691

7.  Advancing our understanding of osteocyte cell biology.

Authors:  Dayong Guo; Lynda F Bonewald
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

Review 8.  Hormonal and systemic regulation of sclerostin.

Authors:  Matthew T Drake; Sundeep Khosla
Journal:  Bone       Date:  2016-12-10       Impact factor: 4.398

9.  Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.

Authors:  S Piemonte; E Romagnoli; C Bratengeier; W Woloszczuk; A Tancredi; J Pepe; C Cipriani; S Minisola
Journal:  J Endocrinol Invest       Date:  2012-07-24       Impact factor: 4.256

10.  OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST.

Authors:  Giuliana Silvestrini; Paola Ballanti; Mariangela Sebastiani; Martina Leopizzi; Maura Di Vito; Ermanno Bonucci
Journal:  J Mol Histol       Date:  2007-12-20       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.